Prenatal And Newborn Genetic Testing Market Report Examines Leading Companies And Growth Opportunities

The prenatal and newborn genetic testing market is positioned for substantial expansion as advances in medical technology and personalized healthcare approaches gain momentum. Growing awareness around early detection and the integration of cutting-edge genomic tools are driving increased demand, pointing to significant market opportunities on the horizon.

Expected Market Size and Growth Trajectory for Prenatal and Newborn Genetic Testing
The prenatal and newborn genetic testing sector is projected to experience rapid growth, reaching a market valuation of $13.65 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 12.6%. The anticipated expansion is largely fueled by the rising adoption of personalized medicine, a surge in early disease detection efforts, broader implementation of newborn screening mandates, increased investments in genomics infrastructure, and more widespread use of digital health technologies. Key market trends include the growing use of non-invasive prenatal testing, the deployment of sophisticated genetic screening panels, the rising incorporation of artificial intelligence in genetic risk analysis, advancements in high-throughput sequencing technologies, and an enhanced focus on identifying congenital disorders at earlier stages.

The prenatal and newborn genetic testing market size has grown rapidly in recent years. It will grow from $7.6 billion in 2025 to $8.51 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing awareness of genetic disorders, expansion of maternal and neonatal healthcare services, rising institutional screening programs, availability of diagnostic laboratories, improvements in genetic testing accuracy.

Download a free sample of the prenatal and newborn genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13158&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Industry Players Dominating the Prenatal and Newborn Genetic Testing Market
Several leading companies are shaping the prenatal and newborn genetic testing landscape, including F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton dic*kinson and Company, Quest Diagnostic Incorporated, Agilent Technologies Inc, Illumina Inc, PerkinElmer Genomics, Quidel Corporation, Bio Rad Laboratories Inc, Qiagen NV, Werfen SA, DiaSorin SpA, BGI Group, Natera Inc, Trinity Biotech plc, Meridian Bioscience Inc, Sekisui Diagnostics, Ariosa Diagnostics Inc, AccuBioTech Co Ltd, Sequenom Inc, and Roche Diagnostics International AG.

A notable collaboration occurred in February 2024, when CooperSurgical Inc., a US-based medical equipment manufacturer, partnered with Fulgent Genetics. This alliance aims to broaden CooperSurgical's offerings by integrating Fulgent Genetics' advanced prenatal and newborn genetic testing capabilities, particularly for families using the Cord Blood Registry. Fulgent Genetics Inc. is recognized for its expertise in delivering cutting-edge genetic testing services within the prenatal and newborn segment.

View the full prenatal and newborn genetic testing market report:
https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovations and Trends Shaping the Prenatal and Newborn Genetic Testing Industry
Companies in this market are increasingly focused on developing innovative, accessible, and affordable screening tests, especially non-invasive prenatal screening (NIPS) methods. These technologies provide accurate and safe genetic risk assessments during pregnancy. For instance, in January 2024, Natera, Inc., a US-based genetic testing company, introduced a fetal RhD non-invasive prenatal test designed to determine fetal RhD status. This test supports healthcare providers amid nationwide shortages of Rho(D) immune globulin (RhIg) by enabling more efficient patient care management. Supported by a comprehensive clinical validation study involving over 650 RhD-negative patients, the test demonstrated 100% sensitivity and over 99% specificity. Its early pregnancy application facilitates timely clinical decisions and enhances patient outcomes.

Detailed Market Segmentation and Forecasts for Prenatal and Newborn Genetic Testing
This report divides the prenatal and newborn genetic testing market into several key segments:
1) Product Type, including Consumables and Instruments
2) Screening Methods such as Non-Invasive Prenatal Testing, Chorionic Villus Sampling, Amniocentesis, Maternal Serum Screening, and others
3) Disease Focus areas, including Down Syndrome, ket*onuria, Cystic Fibrosis, and Sickle Cell Anemia
4) End Users, covering Hospitals, Maternity and Specialty Clinics, and Diagnostic Centers.

Within consumables, the market further includes reagents and assays, sample collection kits, and test kits. Instruments are broken down into polymerase chain reaction (PCR) machines, sequencers, and microarray analyzers, reflecting the technological diversity within the field.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.